160 related articles for article (PubMed ID: 29438906)
1. Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer.
Motylewska E; Stępień T; Borkowska M; Kuzdak K; Siejka A; Komorowski J; Stępień H; Ławnicka H
Cytokine; 2018 May; 105():32-36. PubMed ID: 29438906
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation in IGF-1R, FGFR4 and βKlotho signaling in patients with medullary thyroid cancer.
Motylewska E; Borkowska M; Ławnicka H; Kuzdak K; Siejka A; Świętosławski J; Stepien H; Stepien T
Neuro Endocrinol Lett; 2019 Mar; 40(1):29-35. PubMed ID: 31184820
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum concentrations of IGF-1 and IGF-1R in patients with thyroid cancers.
Lawnicka H; Motylewska E; Borkowska M; Kuzdak K; Siejka A; Swietoslawski J; Stepien H; Stepien T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):77-83. PubMed ID: 31132076
[TBL] [Abstract][Full Text] [Related]
4. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
8. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
9. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
[TBL] [Abstract][Full Text] [Related]
10. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho.
Fu T; Kim YC; Byun S; Kim DH; Seok S; Suino-Powell K; Xu HE; Kemper B; Kemper JK
Mol Endocrinol; 2016 Jan; 30(1):92-103. PubMed ID: 26505219
[TBL] [Abstract][Full Text] [Related]
11. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
[TBL] [Abstract][Full Text] [Related]
12. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho.
Fu T; Choi SE; Kim DH; Seok S; Suino-Powell KM; Xu HE; Kemper JK
Proc Natl Acad Sci U S A; 2012 Oct; 109(40):16137-42. PubMed ID: 22988100
[TBL] [Abstract][Full Text] [Related]
13. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
[TBL] [Abstract][Full Text] [Related]
14. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
15. Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer.
Stępień T; Brożyna M; Kuzdak K; Motylewska E; Komorowski J; Stępień H; Ławnicka H
Dis Markers; 2017; 2017():4962137. PubMed ID: 28255192
[No Abstract] [Full Text] [Related]
16. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma.
Shin JY; Ahn SM
J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926
[TBL] [Abstract][Full Text] [Related]
17. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
[TBL] [Abstract][Full Text] [Related]
18. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
19. Making way for suppressing the FGF19/FGFR4 axis in cancer.
Prieto-Dominguez N; Shull AY; Teng Y
Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
[TBL] [Abstract][Full Text] [Related]
20. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
